Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Stabilization of the Alveolar-Capillary Barrier with ARF6 Inhibitor as a Treatment for Severe Influenza

Award Number: R43HL147780
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/24/2019
PERIOD OF PERFORMANCE END DATE: 03/19/2021

Group Awards By:

View Award Description

Stabilization of the Alveolar-Capillary Barrier with ARF6 Inhibitor as a Treatment for Severe Influenza - SUMMARY Influenza virus infection is one of the most common acute respiratory diseases and remains one of the largest disease burdens on humans, with severe primary viral pneumonia often resulting in death. The pathogenicity of influenza includes a host response that can include a severe systemic inflammatory reaction (cytokine storm) and ensuing vascular leak. Vascular leak is a fundamental element in the pathogenesis of circulatory shock and multiple organ failure, which can lead to death in influenza patients. The laboratories of Dr. Dean Li, co-founder and former Chief Scientific Officer of Navigen, and Dr. Shannon Odelberg, along with Navigen, have demonstrated that vascular leak associated with inflammation is mediated by activation of the small GTPase, ARF6, a common nodal point in the signaling pathways of several inflammatory cytokines and growth factors. Navigen’s objective is to reduce morbidity and mortality associated with influenza infections by modifying this host response. Specifically, we propose to evaluate the efficacy of our small-molecule ARF6 inhibitors with the hypothesis that inhibition of ARF6 will reduce vascular leak elicited by the infection while having no adverse effect on immunity-based clearance of the virus.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2021 ( Subtotal = $0 )
2021	2019	NAVIGEN, INC.	675 S ARAPEEN DR	SALT LAKE CITY	UT	84108	SALT LAKE	USA	Cardiovascular Diseases Research	000	1	7/16/2021	NEW	$0
														Subtotal = $0

Issue Date FY: 2020 ( Subtotal = $0 )
2020	2019	NAVIGEN, INC.	383 COLOROW DR	SALT LAKE CITY	UT	84108	SALT LAKE	USA	Cardiovascular Diseases Research	000	1	11/19/2019	NEW	$0
2020	2019	NAVIGEN, INC.	383 COLOROW DR	SALT LAKE CITY	UT	84108	SALT LAKE	USA	Cardiovascular Diseases Research	002	1	3/13/2020	NEW	$0
2020	2019	NAVIGEN, INC.	383 COLOROW DR	SALT LAKE CITY	UT	84108	SALT LAKE	USA	Cardiovascular Diseases Research	001	1	1/7/2020	NEW	$0
														Subtotal = $0

Issue Date FY: 2019 ( Subtotal = $268,075 )
2019	2019	NAVIGEN, INC.	383 COLOROW DR	SALT LAKE CITY	UT	84108	SALT LAKE	USA	Cardiovascular Diseases Research	000	1	9/23/2019	NEW	$268,075
														Subtotal = $268,075

Grand Total All Awards = $268,075

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Stabilization of the Alveolar-Capillary Barrier with ARF6 Inhibitor as a Treatment for Severe Influenza

Award Number: R43HL147780

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/24/2019

PERIOD OF PERFORMANCE END DATE: 03/19/2021

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer